Strides Pharma Gets Usfda Approval For Generic Ibuprofen Oral Suspension

Strides Pharma Gets Usfda Approval For Generic Ibuprofen Oral Suspension

By, Admin 31 May 2022

The Product Is Bioequivalent And Therapeutically Equivalent To The Reference Listed Drug Motrin Oral Suspension, 100 Mg/5 Ml, Of Mcneil Consumer Healthcare (Mcneil), It Added. Strides Pharma Science Ltd (Strides) On Monday Said Its Singapore-Based Arm Has Received Approval From The Us Health Regulator For Generic Ibuprofen Oral Suspension, Which Is Used To Relieve Pain From Various Conditions. The Approval Granted To The Company'S Stepdown Wholly-Owned Subsidiary Strides Pharma Global Pte Ltd, Singapore, By The Us Food And Drug Administration (Usfda) Is For Ibuprofen Oral Suspension Of The Strength Of 100 Mg/5 Ml, The Company Said In A Statement. The Product Is Bioequivalent And Therapeutically Equivalent To The Reference Listed Drug Motrin Oral Suspension, 100 Mg/5 Ml, Of Mcneil Consumer Healthcare (Mcneil), It Added. The Product Will Be Manufactured At The Company'S Facility In Bengaluru And Will Be Marketed By Strides Pharma Inc In The Us Market. Citing Iqvia Mat March 2022 Data, The Company Said The Us Market For Ibuprofen Oral Suspension 100 Mg/5 Ml Is Approximately Usd 66 Million. Strides Said It Has A Total Of 274 Abbreviated New Drug Application (Anda) Filings With Usfda, Of Which 250 Andas Have Been Approved And 24 Are Pending Approval. It Currently Has Around 60 Commercialised Products In The Us And Has Set A Target To Launch Around 20 New Products Every Year From The Combined Portfolio, Strides Noted

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!